Imbio PHA (4.0.0) vs Aorta-CAD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Imbio PHA (4.0.0)

by Imbio (a subsidiary of 4DMedical)

Aorta-CAD

by Imagen Technologies

AI Verdict

Tool A specializes in analyzing CT pulmonary angiogram (CTPA) scans to measure cardiac structures for pulmonary embolism and hypertension risk. In contrast, Tool B focuses on detecting signs of aortic atherosclerosis and ectasia on chest X-rays. While both are FDA-cleared AI tools for cardiovascular imaging, their distinct input modalities and specific diagnostic targets make them suitable for different clinical scenarios.

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA if your clinical workflow involves analyzing CT pulmonary angiogram (CTPA) scans for detailed cardiac structure measurements. This tool is ideal for aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension by automatically calculating RV/LV and PA/Ao ratios. It provides rapid, comprehensive assessment for pulmonologists and cardiologists requiring precise quantitative data from CTPA images.

View Imbio PHA (4.0.0) →

Choose Aorta-CAD if…

Choose Aorta-CAD if you need an AI-powered assistant for detecting signs of Aortic Atherosclerosis and Aortic Ectasia on standard chest X-rays. This cloud-based solution is best suited for improving the accuracy of frontline diagnostic imaging, particularly for radiologists and primary care physicians interpreting chest X-rays. It seamlessly integrates into existing workflows to highlight potential findings, reducing misses for these aortic conditions.

View Aorta-CAD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Imbio PHA (4.0.0)	Aorta-CAD
Deployment	Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).	Cloud-based software that integrates into existing chest X-ray workflows and Picture Archiving and Communication System (PACS) viewers.
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Imbio PHA (4.0.0)

Tool A offers more flexible deployment options (Cloud, Enterprise on-premise, or via partners), which can enhance usability for organizations with diverse IT infrastructures. It also explicitly mentions integration with native DICOM tools and workflows, along with generating PDF reports, indicating robust integration capabilities within existing radiology environments.

Clinical Value

Aorta-CAD

While both tools are FDA-cleared and provide clinical utility, Tool B explicitly quantifies its clinical impact with demonstrated results: a 62% relative reduction in misses for aortic calcification and a 35% relative reduction in misses for dilated aorta in clinical studies. This provides a clear, measurable benefit to diagnostic accuracy.

Pricing & Value

Tie

Both Tool A and Tool B require direct contact for pricing information, indicating a lack of public pricing transparency. Without specific pricing details or further information on their value propositions, it is not possible to differentiate them on this dimension.

Enterprise Readiness

Imbio PHA (4.0.0)

Tool A demonstrates superior enterprise readiness due to its flexible deployment options, including Cloud, Enterprise (on-premise), or via partners. This adaptability allows it to integrate into a wider range of healthcare IT environments compared to Tool B's cloud-only deployment. Both are FDA-cleared and HIPAA compliant with BAA.

Innovation

Tie

Both tools leverage AI and deep learning algorithms for medical image analysis in their respective specialties, representing innovative applications of technology in healthcare. Neither tool's description provides sufficient detail to distinguish one as significantly more innovative in its core algorithmic approach or technological advancement than the other.

Support & Docs

Tie

The provided structured facts do not contain any specific information regarding support channels, documentation availability, or service level agreements for either Tool A or Tool B. Without this crucial information, it is impossible to make a distinction between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Imbio PHA (4.0.0)	Aorta-CAD
Product Name	Imbio PHA (4.0.0)	Aorta-CAD
Company	Imbio	Imagen Technologies
Input Imaging Modality	CT pulmonary angiogram (CTPA) scans	Chest X-rays
Primary Conditions Addressed	Potential right ventricular dilation, pulmonary embolism and hypertension	Aortic Atherosclerosis and Aortic Ectasia
Key Automated Measurements/Detections	Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios	Detects and highlights radiographic findings suggestive of Aortic Atherosclerosis and Aortic Ectasia
Output & Integration	Generates annotated DICOM images; Provides summary reports in PDF format; Integrates with native DICOM tools and workflows	Creates annotations via an overlay that can be toggled on/off; Seamlessly integrates into existing X-ray reading workflows

Videos

Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Aorta-CAD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What imaging modalities do these AI tools analyze?

Imbio PHA (4.0.0) processes CT pulmonary angiogram (CTPA) scans to measure cardiac structures. Aorta-CAD by Imagen Technologies, in contrast, analyzes chest X-rays to detect signs of Aortic Atherosclerosis and Aortic Ectasia.

What specific cardiac conditions or findings do these AI tools assist in identifying?

Imbio PHA (4.0.0) aids in assessing potential right ventricular dilation and supports the diagnosis and risk stratification of pulmonary embolism and hypertension. Aorta-CAD assists physicians in detecting radiographic findings suggestive of Aortic Atherosclerosis and Aortic Ectasia.

What type of output or reporting does each AI tool provide?

Imbio PHA (4.0.0) generates annotated DICOM images and provides summary reports in PDF format. Aorta-CAD creates annotations via an overlay that can be toggled on or off to highlight findings on chest X-rays.

Are there any reported clinical performance metrics for these tools?

Aorta-CAD has demonstrated a 62% relative reduction in misses for aortic calcification and a 35% relative reduction in misses for dilated aorta in a clinical study. Imbio PHA (4.0.0) is noted for providing rapid, fully-automated assessment, typically in minutes.

Which medical specialties are these tools primarily designed to support?

Imbio PHA (4.0.0) is intended for Cardiology, Pulmonology, and Radiology specialties. Aorta-CAD supports Cardiology, Internal Medicine, and Radiology, including assistance for primary care physicians.